213Bi-[DOTA0,Tyr3]octreotide peptide receptor radionuclide therapy of pancreatic tumors in a preclinical animal model

Clinical Cancer Research

Volumn 12, Issue 3 I, 2006, Pages 897-903

  Norenberg, Jeffrey P ^a   Krenning, Boudewijn J ^a,b   Konings, Inge R H M ^a,b   Kusewitt, Donna F ^b   Nayak, Tapan K ^a   Anderson, Tamara L ^a   De Jong, Marion ^c   Garmestani, Kayhan ^d   Brechbiel, Martin W ^d   Kvols, Larry K ^b  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OCTREOTIDE; SOMATOSTATIN RECEPTOR; BISMUTH; DRUG DERIVATIVE; OCTREOTIDE, DOTA TYR(3); OCTREOTIDE, DOTA-TYR(3)-; RADIOISOTOPE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BLOOD TOXICITY; CANCER RADIOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG SAFETY; DRUG STERILITY; HISTOPATHOLOGY; HYPERPLASIA; HYPOPLASIA; INTERSTITIAL NEPHRITIS; ISOTOPE LABELING; NEPHROTOXICITY; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; RADIOACTIVITY; RAT; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR GROWTH; ANIMAL; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECT; DRUG SCREENING; LEWIS RAT; MALE; PANCREAS TUMOR; TIME;

ANIMALS; BISMUTH; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; MALE; OCTREOTIDE; PANCREATIC NEOPLASMS; RADIOISOTOPES; RATS; RATS, INBRED LEW; RECEPTORS, SOMATOSTATIN; TIME FACTORS;

EID: 32944476632     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1264     Document Type: Article

References (38)

1. Reubi JC, Lang W, Maurer R, Koper JW, Lamberts SW. Distribution and biochemical characterization of somatostatin receptors in tumors of the human central nervous system. Cancer Res 1987;47:5758-64.
2. Reubi JC, Krenning E, Lamberts SW, Kvols L. In vitro detection of somatostatin receptors in human tumors. Metabolism 1992;41:104-10.
3. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol 1999;20:157-98.
4. Rens-Domiano S, Reisine T. Biochemical and functional properties of somatostatin receptors. J Neurochem 1992;58:1987-96.
5. Oberg K. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours. Ann Oncol 2001;12: S111-4.
6. Lamberts SW, Krenning EP, Klijn JG, Reubi JC. The clinical use of somatostatin analogues in the treatment of cancer. Baillieres Clin Endocrinol Metab 1990;4:29-49.
7. Kvols LK. Metastatic carcinoid tumors and the carcinoid syndrome. A selective review of chemotherapy and hormonal therapy. Am J Med 1986;81:49-55.
8. Kvols LK, Brown ML, O'Connor MK, et al. Evaluation of a radiolabeled somatostatin analog (I-123 octreotide) in the detection and localization of carcinoid and islet cell tumors. Radiology 1993;187:129-33.
9. Leitha T, Meghdadi S, Studnicka M, et al. The role of iodine-123-tyr-3-octreotide scintigraphy in the staging of small-cell lung cancer. J Nucl Med 1993;34:1397-402.
10. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003;24:389-427.
11. Otte A, Herrmann R, Heppeler A, et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med 1999;26:1439-47.
12. Lambert B, Cybulla M, Weiner SM, et al. Renal toxicity after radionuclide therapy. Radiat Res 2004;161:607-11.
13. 90Y-DOTATOC. Eur J Nucl Med Mol Imaging 2002;29:435.
14. Krenning EP, Kwekkeboom DJ, Valkema R, Pauwels S, Kvols LK, De Jong M. Peptide receptor radionuclide therapy. Ann N Y Acad Sci 2004;1014:234-45.
15. Lewington VJ. Targeted radionuclide therapy for neuroendocrine tumours. Endocr Relat Cancer 2003;10:497-501.
16. 211At-labeled guanidinomethyl halobenzoyl octreotate conjugates: potential peptide radiotherapeutics for somatostatin receptor-positive cancers. Peptides 2004;25:2087-97.
17. McDevitt MR, Sgouros G, Finn RD, et al. Radioimmunotherapy with α-emitting nuclides. Eur J Nucl Med 1998;25:1341-51.
18. 225Ac as a source of α-particles in radioimmunotherapy. Nucl Med Commun 1993;14:121-5.
19. 213Bi generator: development of new methods, quantitative characterization, and implications for clinical use. Appl Radiat Isot 2001;55:667-78.
20. McDevitt MR, Scheinberg DA. Ac-225 and her daughters: the many faces of shiva. Cell Death Differ 2002;9:593-4.
21. 90Y-labeled CO17-1A fab′ fragments in a human colonic cancer model. Cancer Res 1999;59:2635-43.
22. 213Bi-rituximab versus external γ irradiation for the treatment of B-CLL patients: relative biological efficacy with respect to apoptosis induction and chromosomal damage. Eur J Nucl Med Mol Imaging 2003;30:1357-64.
23. 225Ac. Radiochim Acta 1997;79:141-4.
24. Comstock TJ. Assessment of renal function. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, editors. Pharmacotherapy: a pathophysiologic approach. 4th ed. New York: McGraw-Hill Medical Publishing Division; 1999. p. 686-705.
25. Quintanar-Stephano A, Munoz Fernandez L, Quintanar JL, Kovacs K. Cysts in the rat adenohypophysis: incidence and histology. Endocr Pathol 2001;12:63-71.
26. Milenic DE, Brady ED, Brechbiel MW. Antibody-targeted radiation cancer therapy. Nat Rev Drug Discov 2004;3:488-99.
27. Breeman WA, Bakker WH, DeJong M, et al. Studies on radiolabeled somatostatin analogues in rats and in patients. Q J Nucl Med 1996;40:209-20.
28. 111In-DTPA-D-Phe1)-octreotide (OctreoScan111). Acta Oncol 1993;32:177-82.
29. 90Y-labeled somatostatin analogs. J Nucl Med 2005;46:13-7S.
30. Lewis JS, Wang M, Laforest R, et al. Toxicity and dosimetry of (177)Lu-DOTA-Y3-octreotate in a rat model. Int J Cancer 2001;94:873-7.
31. Wang Q, Graham K, Schauer T, et al. Pharmacological properties of hydrophilic and lipophilic derivatives of octreotate. Nucl Med Biol 2004;31:21-30.
32. 90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur J Nucl Med Mol Imaging 2003;30:207-16.
33. Kimura N, Schindler M, Kasai N, Kimura I. Immunohistochemical localization of somatostatin receptor type 2A in rat and human tissues. Endocr J 2001;48:95-102.
34. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 2005;46:62-6S.
35. Rizvi SM, Allen BJ, Tian Z, Goozee G, Sarkar S. In vitro and preclinical studies of targeted α therapy (TAT) for colorectal cancer. Colorectal Dis 2001;3:345-53.
36. Zalutsky MR, Bigner DD. Radioimmunotherapy with α-particle emitting radioimmunoconjugates. Acta Oncol 1996;35:373-9.
37. Mulford DA, Scheinberg DA, Jurcic JG. The promise of targeted α-particle therapy. J Nucl Med 2005;46:199-204S.
38. Kassis AI, Adelstein SJ. Radiobiologic principles in radionuclide therapy. J Nucl Med 2005;46:4-12S.